RecruitingPhase 1NCT06179069

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

Sponsor

Zai Lab (Shanghai) Co., Ltd.

Enrollment

339 participants

Start Date

Jan 23, 2024

Study Type

INTERVENTIONAL

Conditions

SCLC

Summary

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called ZL-1310 for people with small cell lung cancer (SCLC) — a fast-growing type of lung cancer. The drug is given by IV and researchers are studying how safe and effective it is, including whether it works for people whose cancer has spread to the brain. **You may be eligible if...** - You have been diagnosed with metastatic or extensive-stage small cell lung cancer - Your cancer got worse during or after platinum-based chemotherapy (the standard first treatment) - You are in good enough health to participate in a clinical trial - You are willing to provide a tissue sample (biopsy) **You may NOT be eligible if...** - Your SCLC developed from a different type of cancer (transformed type) - You have certain serious heart conditions or other major health problems - You are pregnant or breastfeeding - You have had prior treatment with a similar class of drug (depending on the study group) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZL-1310

Drug: ZL-1310

DRUGAtezolizumab

Drug Atezolizumab

DRUGCarboplatin

Drug Carboplatin

Locations(38)

Zai Lab Site 2005

Duarte, California, United States

Zai Lab Site 2030

New Haven, Connecticut, United States

Zai Lab Site 2026

Sarasota, Florida, United States

Zai Lab Site 2013

Detroit, Michigan, United States

Zai Lab Site 2001

Hackensack, New Jersey, United States

Zai Lab Site 2002

Buffalo, New York, United States

Zai Lab Site 2018

Durham, North Carolina, United States

Zai Lab Site 2024

Cleveland, Ohio, United States

Zai Lab Site 2029

Pittsburgh, Pennsylvania, United States

Zai Lab Site 2012

Charleston, South Carolina, United States

Zai Lab Site 2006

Fairfax, Virginia, United States

Zai Lab Site 1004

Hefei, Anhui, China

Zai Lab Site 1005

Beijing, Beijing Municipality, China

Zai Lab Site 1012

Xiamen, Fujian, China

Zai Lab Site 1001

Guangzhou, Guangdong, China

Zai Lab Site 1009

Harbin, Heilongjiang, China

Zai Lab Site 1006

Zhengzhou, Henan, China

Zai Lab 1002

Wuhan, Hubei, China

Zai Lab Site 1014

Changsha, Hunan, China

Zai Lab Site 1016

Nanjing, Jiangsu, China

Zai Lab Site 1003

Nanchang, Jiangxi, China

Zai Lab Site 1008

Ch’ang-ch’un, Jilin, China

Zai Lab Site 1017

Shenyang, Liaoning, China

Zai Lab Site 1015

Xi'an, Shaanxi, China

Zai Lab Site 1011

Jinan, Shandong, China

Zai Lab Site 1010

Shanghai, Shanghai Municipality, China

Zai Lab Site 1013

Chengdu, Sichaun, China

Zai Lab Site 8002

Barcelona, Barcelona, Spain

Zai Lab Site 8003

Madrid, Madrid, Spain

Zai Lab Site 8006

Madrid, Madrid, Spain

Zai Lab Site 8005

Seville, Sevilla, Spain

Zai Lab Site 8004

Valencia, Valencia, Spain

Zai Lab Site 8001

Valencia, Valencia, Spain

Zai Lab Site 8007

Barcelona, Spain

Zai Lab Site 8009

Madrid, Spain

Zai Lab Site 8008

Málaga, Spain

Zai Lab Site 8010

Pozuelo de Alarcón, Spain

Zai Lab Site 8011

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06179069

Related Trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

NCT059030924 locations

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

NCT074166952 locations

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

NCT075088521 location

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

NCT048263411 location

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT0665722216 locations